SA国际传媒

, an early-stage oncology startup, launched on Thursday armed with $125 million in financing to advance its suite of technology for cancer treatment.聽

The Massachusetts-based company raised a $90 million Series A round led by with additional funding from , and earlier this week.聽

Nested Therapeutics developed a drug discovery platform that allows the company to look for alternative ways for drugs to find cancer cells and kill them.聽

Using a multidisciplinary approach that leverages computational engineering, biology and a handful of niche fields in life science, 鈥�This opens doors to design novel small molecules for previously known targets with well-understood biology and to target what has been previously undruggable,鈥� said Klaus Hoeflich, CTO and co-founder of Nested.聽

鈥楾ired targets鈥�

The pharmaceuticals industry has been plagued with the issue of finding new targets鈥攑roteins in disease cells the drug can 鈥渟tick鈥� to in the body. For a long time, armed with a small set of targets researchers have stumbled upon over the years, scientists would look for ways to make drugs that would actually stick, and sometimes come up short.聽

But that strategy needs a massive overhaul, according to , a health-focused partner at . In order to treat previously untreatable diseases in the body, the scientific community needs to make a concerted effort to look for novel targets the drug can find.聽

Over $1.6 billion has been poured into drug discovery startups so far this year, according to SA国际传媒 data.聽

Since 2017, venture firms have embraced drug discovery startups for their ability to make drug investment overall less risky. Using artificial intelligence and machine learning, some of these platforms have the ability to more or less predict how well a specific drug will fare during clinical trials, often called the 鈥淰alley of Death鈥� where most drugs fail, sinking billions of dollars with them.

But the process starts with looking for new targets to deliver these treatments.聽

鈥淭he way that the industry has worked so far is typically in academia, you might stumble across an interesting target,鈥� Choi said. 鈥淎nd there hasn’t really been a directed effort to look for these targets until now.鈥�

滨濒濒耻蝉迟谤补迟颈辞苍:听